A complement and immunoglobulin blood test panel examines two different parts of immune defense. C3, C4, and CH50 assess complement proteins that tag microbes, amplify inflammation, and help damage susceptible pathogens. IgG, IgA, and IgM measure major antibody classes made by B cells. Together, these tests can reveal broad patterns of complement consumption, inherited pathway deficiency, antibody deficiency, chronic immune stimulation, or protein loss.
The panel does not produce one overall “immune score,” and a normal result does not guarantee normal immunity or exclude a clinically important immune disorder. C3 and C4 are concentrations, while CH50 is a functional assay. Immunoglobulin levels show how much antibody is present but not whether it recognizes vaccines or infections effectively. Interpretation depends on age, symptoms, medications, recent infection, liver and kidney health, specimen handling, and previous results. Abnormal findings usually lead to focused follow-up rather than a diagnosis from the panel alone. The clinical question determines which follow-up test has the greatest practical value for interpretation.
- C3 and C4 measure complement protein amounts: Low levels may reflect consumption, inherited deficiency, reduced production, or protein loss.
- CH50 measures classical and terminal pathway function: A very low result can signal a component defect, drug effect, consumption, or specimen degradation.
- IgG is the main circulating antibody class: Low IgG raises concern for antibody deficiency, medication effects, or protein loss.
- IgA supports mucosal defense: Very low IgA can affect respiratory and intestinal immunity and alter some celiac blood tests.
- IgM is the early-response antibody: Low or high values require interpretation with the other immunoglobulins and clinical history.
- No fasting is usually required: Accurate medication history and correct handling of the CH50 sample are more important.
Table of Contents
- Two Immune Systems in One Panel
- Why the Panel May Be Ordered
- What Each Test Contributes
- Collection, Preparation, and Reference Ranges
- Interpreting Complement Patterns
- Interpreting Immunoglobulin Patterns
- Combined Results and Next Tests
- Limitations and When Results Need Fast Action
Two Immune Systems in One Panel
Complement and antibodies cooperate, but they are not interchangeable. Complement is largely part of innate immunity, which reacts rapidly to infection and tissue injury. Immunoglobulins belong to adaptive immunity, which develops targeted recognition and memory after infection or vaccination.
The complement cascade can begin through classical, lectin, or alternative pathways. The classical pathway is often activated by antibodies bound to a target. All pathways converge at C3 and can proceed to C5 and the membrane attack complex, C5b-9. Complement also coats microbes so phagocytes can ingest them and releases fragments that recruit inflammatory cells.
Immunoglobulins are antibodies produced by plasma cells after B-cell activation. The panel usually includes:
- IgG, the most abundant antibody class in blood and a major source of long-term systemic protection
- IgA, concentrated at mucosal surfaces such as the respiratory and gastrointestinal tracts
- IgM, the first major antibody made during a new response and an efficient activator of classical complement
The panel combines concentration and function. C3, C4, IgG, IgA, and IgM are quantitative protein measurements. CH50 asks whether the classical and terminal complement components can complete a functional reaction. A low concentration does not always mean absent function, and a normal concentration does not prove that a protein works properly.
This is why the panel should not be reduced to “high means inflammation” or “low means weak immunity.” Low complement may reflect active consumption during inflammation, while high immunoglobulins may come from chronic immune stimulation rather than better protection. The pattern and clinical setting determine the meaning.
The two systems also fail in different ways. Complement defects often change susceptibility to particular bacteria or produce autoimmune and kidney problems through poor clearance of immune complexes. Antibody defects more often impair recognition and opsonization of respiratory pathogens. A patient can have one normal system and one abnormal system, so a single normal subsection of the panel should not cancel an abnormal finding elsewhere.
Results also describe the blood sample at one moment. Complement consumption can fluctuate with a flare, infection, or treatment. Immunoglobulin concentrations change more slowly but can be altered by infusion, protein loss, B-cell-depleting drugs, or recovery after therapy. Comparing the panel with older values often reveals whether the pattern is longstanding, newly acquired, or temporary.
Why the Panel May Be Ordered
Clinicians may order the panel when symptoms could arise from complement deficiency, antibody deficiency, immune-complex disease, or a secondary loss of immune proteins. It is especially useful as a broad first look when the history does not point clearly to one pathway.
Common reasons include:
- Recurrent bacterial sinus, ear, lung, or bloodstream infections
- Repeated pneumonia or bronchiectasis
- Invasive meningococcal or gonococcal infection
- Early or unusual autoimmune disease
- Suspected systemic lupus erythematosus or immune-complex kidney disease
- Unexplained low total protein or globulin
- Chronic diarrhea, malabsorption, or protein-losing enteropathy
- Nephrotic-range protein loss
- Enlarged spleen, lymph nodes, or unexplained blood-count abnormalities
- Monitoring of a known immune disorder or complement-blocking treatment
The infection history matters more than the total number of minor illnesses. Organisms, infection sites, cultures, need for intravenous antibiotics, hospitalizations, and imaging can show whether the pattern fits antibody failure or complement deficiency.
Antibody deficiencies commonly cause recurrent sinopulmonary infection with encapsulated bacteria. Terminal complement defects are particularly associated with invasive Neisseria. Early classical complement deficiencies can increase both infection risk and susceptibility to lupus-like autoimmune disease.
The panel may also be ordered during autoimmune evaluation. Low C3 and C4 can support complement consumption in active immune-complex disease, while polyclonal elevation of IgG may accompany chronic inflammation. These findings are supportive rather than diagnostic and must be combined with disease-specific tests, symptoms, urine studies, and organ assessment.
A broad panel can reveal more than one process. A patient with autoimmune disease may have low complement from consumption and low IgG from medication. Another may have high IgG from chronic liver disease and normal complement function. The tests should be interpreted individually before they are combined.
The panel may be reasonable before specialist referral when recurrent infections are documented, but it should not replace a basic evaluation. A complete blood count can reveal neutropenia or lymphopenia, albumin can show protein loss or reduced synthesis, and urinalysis can identify kidney involvement. These inexpensive tests often explain why several immune proteins are abnormal or show that a different immune pathway needs attention.
In children, the threshold for concern depends on age, growth, vaccine history, and the type of infection. Day-care exposure can cause frequent viral illnesses without immune deficiency. Repeated bacterial pneumonia, invasive infection, poor growth, unusual organisms, or complications such as bronchiectasis carry more weight than the number of uncomplicated colds.
What Each Test Contributes
C3
C3 is the central component shared by all three complement pathways. Cleaved C3b coats targets and helps create C5 convertase. Low complement C3 can result from consumption, inherited deficiency, reduced liver production, or protein loss. Isolated low C3 with relatively preserved C4 can suggest alternative-pathway activation, although the pattern is not specific.
High C3 may occur as part of an acute-phase response and is generally less diagnostically useful than a low value. A normal C3 does not exclude a terminal-component deficiency or a regulatory complement disorder.
C4
C4 participates in the classical and lectin pathways. Low complement C4 is common during classical-pathway consumption, as in some lupus activity, mixed cryoglobulinemia, and hereditary angioedema due to C1 inhibitor deficiency. Genetic copy-number differences can also produce a chronically low baseline.
C4 may be normal in alternative-pathway activation. Like C3, it is made mainly by the liver and can be affected by systemic inflammation, synthesis, and loss.
CH50
The CH50 test measures the combined function of the classical and terminal complement pathways. It depends on C1, C2, C4, C3, and C5 through C9. A complete deficiency of one required component may make CH50 absent or nearly absent.
CH50 is highly sensitive to sample handling. A low result may reflect delayed processing, improper temperature, repeated freeze-thaw cycles, or a complement inhibitor such as eculizumab. It is not simply the sum of C3 and C4 concentrations.
IgG
IgG provides most long-term antibody protection in blood and tissues. Low IgG can occur in common variable immunodeficiency, agammaglobulinemia, medication-induced deficiency, lymphoid malignancy, nephrotic syndrome, or intestinal protein loss.
High IgG may be polyclonal, reflecting chronic infection, autoimmune disease, or liver disease, or monoclonal, reflecting a plasma-cell or B-cell clone. Serum protein electrophoresis and immunofixation distinguish these patterns better than total IgG alone.
IgA
IgA protects mucosal surfaces. Selective IgA deficiency produces very low IgA with generally normal IgG and IgM. Low IgA may also occur within CVID or broader combined immune disorders. An IgA result is important when interpreting IgA-based celiac serology because severe deficiency can cause a false-negative tissue transglutaminase IgA test.
High IgA can accompany chronic liver disease, inflammation, infection, or monoclonal gammopathy.
IgM
IgM is produced early after exposure and activates classical complement efficiently. Low IgM may accompany CVID, medication effects, protein loss, or selected primary antibody disorders. High IgM can occur in recent infection, liver disease, autoimmunity, monoclonal gammopathy, or hyper-IgM syndromes when paired with low IgG and IgA.
Collection, Preparation, and Reference Ranges
The panel uses venous blood. Fasting is usually unnecessary unless it is being collected with tests that require fasting. The patient should provide a complete medication list and report recent immunoglobulin infusions, plasma products, major infection, vaccination, surgery, or complement-directed treatment.
The immunoglobulin and component concentration samples are generally stable under standard laboratory conditions. CH50 often requires much stricter handling. Some laboratories require a plain red-top tube, prompt serum separation, and immediate freezing at −70°C or below. The collection center must follow the performing laboratory’s instructions.
Reference intervals are age dependent, especially for immunoglobulins in children. Newborn IgG reflects maternal transfer and then falls before the infant’s own production rises. IgA develops more gradually. Adult ranges also vary by laboratory method and population.
There is no universal numeric normal range for CH50. Different methods report different units. C3 and C4 ranges also vary, and a value from one laboratory should not be compared directly with another laboratory’s interval.
A useful report includes:
- The result and units for every analyte
- The age-adjusted reference interval
- The CH50 method and specimen comments
- The date and laboratory
- Whether immunoglobulin replacement or complement-blocking therapy was in use
Serial monitoring is easiest when the same laboratory and method are used. A small change across different platforms may be analytical rather than biological.
Before testing, patients can improve interpretation by bringing a list of prior infections, vaccine dates, infusion dates, and older laboratory reports. The clinician should know whether the sample was drawn before or after a complement inhibitor dose and whether intravenous or subcutaneous immunoglobulin was recently given. These details may prevent an expected treatment effect from being mislabeled as a new disease.
Acute illness can change several values at once. C3, C4, and immunoglobulins may rise as part of inflammation, while severe infection may consume complement. A stable repeat sample can help when a borderline result does not fit the clinical history. Repeat timing should reflect the question rather than a fixed interval.
Interpreting Complement Patterns
C3, C4, and CH50 create a useful but incomplete map.
| C3 | C4 | CH50 | Possible interpretation |
|---|---|---|---|
| Low | Low | Low | Classical-pathway consumption, severe systemic consumption, reduced synthesis, or broad complement loss |
| Low | Normal | Low or normal | Alternative-pathway activation, C3 deficiency, or regulatory abnormality |
| Normal | Low | Low | Early classical consumption or deficiency, C1 inhibitor-related consumption, or chronically low C4 baseline |
| Normal | Normal | Very low | Terminal-component deficiency, functional component defect, complement inhibitor, or poor specimen handling |
| Normal | Normal | Normal | Major complete classical/terminal deficiency less likely; alternative or lectin pathway and regulatory disorders may remain |
CH50 should often be paired with AH50 when inherited complement deficiency is suspected. Low CH50 with normal AH50 points toward C1, C2, or C4. Low results in both suggest C3 or C5–C9 deficiency, consumption, treatment effect, or specimen degradation. Normal CH50 with low AH50 suggests factor B, factor D, properdin, or another alternative-pathway problem.
Complement concentrations alone cannot reliably separate inherited deficiency from consumption. A complete genetic deficiency usually produces a stable pattern. Acquired consumption often changes with disease activity and may reduce several proteins together. Individual component tests, activation markers, functional assays, and genetic testing may be needed.
In autoimmune disease, trends should be interpreted with clinical findings. Falling C3 and C4 can accompany active lupus nephritis, but treatment should not be changed solely because one value moves. Urinalysis, proteinuria, kidney function, anti-dsDNA antibodies, symptoms, and examination provide essential context.
Interpreting Immunoglobulin Patterns
The three immunoglobulin classes show whether antibody concentrations are broadly reduced, selectively abnormal, or increased.
| IgG | IgA | IgM | Patterns to consider |
|---|---|---|---|
| Low | Low | Low or normal | CVID, medication effect, protein loss, lymphoid disease, or broader immunodeficiency |
| Normal | Very low | Normal | Selective IgA deficiency |
| Low | Low | High | Hyper-IgM phenotype, chronic stimulation, or selected lymphoid disorders |
| High | High | High | Polyclonal immune activation, chronic liver disease, infection, or autoimmunity |
| High in one class | Other classes reduced or normal | Variable | Monoclonal gammopathy or class-specific immune stimulation; electrophoresis may be needed |
Low immunoglobulins should be repeated and evaluated for secondary causes. Urine protein, albumin, stool protein-loss studies, medication timing, HIV testing, blood counts, and serum protein electrophoresis may be appropriate.
Quantity does not prove antibody quality. A patient with normal IgG can still have specific antibody deficiency and poor response to pneumococcal polysaccharides. Conversely, mild low IgG may coexist with adequate vaccine responses and few infections. Vaccine titers and clinical burden decide whether a functional antibody problem is present.
High immunoglobulins should be classified as polyclonal or monoclonal. A broad increase across many antibody clones is common in inflammation and liver disease. A narrow monoclonal protein requires evaluation with serum protein electrophoresis, immunofixation, and sometimes free light chains.
Combined Results and Next Tests
Combined abnormalities can reveal a shared secondary cause. Low C3, C4, IgG, IgA, albumin, and total protein may suggest major protein loss or reduced liver synthesis. Low complement with high polyclonal IgG can occur in immune-complex disease because antibodies drive complement activation. Low IgG with normal complement may point more strongly toward an antibody-production problem.
The next test should answer the uncertainty left by the pattern:
- Repeat unexpected abnormalities. Confirm low values when the patient is stable and ensure proper CH50 handling.
- Add AH50 for pathway localization. This is especially important for recurrent meningococcal disease or very low CH50.
- Measure vaccine responses. Pneumococcal, tetanus, and diphtheria antibodies assess specific antibody function.
- Order lymphocyte subsets. T-cell, B-cell, and natural killer cell counts can identify a broader immune disorder.
- Evaluate protein loss and synthesis. Albumin, urine protein, liver tests, and stool alpha-1 antitrypsin may explain multiple low proteins.
- Characterize elevated immunoglobulins. SPEP, immunofixation, and serum free light chains distinguish polyclonal from monoclonal patterns.
- Use individual complement tests. C1, C2, C5–C9, factor B, factor H, factor I, or properdin may follow an abnormal functional screen.
- Consider genetic testing. A molecular panel may confirm an inherited complement or antibody deficiency when the phenotype and laboratory pattern support it.
The panel can also guide referral. Recurrent infections with low immunoglobulins usually warrant clinical immunology evaluation. Low complement with kidney findings may require nephrology or rheumatology. A monoclonal pattern may need hematology assessment.
Treatment should not be based on one panel in isolation. Immunoglobulin replacement requires evidence of clinically meaningful antibody deficiency and specialist assessment. Complement deficiency management may involve vaccination, antibiotic prevention, emergency education, and treatment of the underlying acquired disease.
If repeat testing is normal, the original abnormality should still be interpreted rather than erased. A transient low complement result may document consumption during an acute event. A temporary low IgG may identify medication effect or protein loss that later resolved. The timeline can be clinically useful even when no chronic immune deficiency is found.
When a hereditary disorder is confirmed, relatives may need testing. The appropriate test depends on the defect: functional complement assays, individual component levels, quantitative immunoglobulins, vaccine responses, or targeted genetic analysis. Testing healthy relatives without first defining the affected person’s abnormality can produce ambiguous results and unnecessary concern.
Limitations and When Results Need Fast Action
This panel does not assess every immune function. It omits vaccine-specific antibodies, IgG subclasses, B-cell maturation, T-cell function, neutrophil killing, AH50, lectin-pathway activity, and many complement regulators. Normal results can coexist with important immune disease.
Common interpretation errors include:
- Treating all low complement as inherited deficiency
- Assuming high complement proves active inflammation
- Diagnosing CVID from one low IgG result
- Ignoring age-specific immunoglobulin ranges
- Comparing CH50 values from different methods
- Forgetting that immunoglobulin replacement raises IgG and donor vaccine titers
- Missing protein loss when several proteins and albumin are low
- Calling a monoclonal immunoglobulin increase “strong immunity”
Urgent care is needed for symptoms of meningitis or sepsis, including sudden fever, severe headache, stiff neck, confusion, rapidly spreading purple spots, fast breathing, or severe weakness. This is especially important for known terminal complement deficiency or complement-inhibitor treatment.
Breathing difficulty, low oxygen, chest pain, or severe pneumonia symptoms also require prompt assessment. Patients with significant antibody deficiency can deteriorate quickly even when early symptoms seem routine.
For nonurgent abnormal results, preserve the full report and review it with the ordering clinician. The date, units, reference interval, treatment status, infection status, and specimen comments can be as important as the number. A focused repeat and targeted second-line tests usually provide more clarity than repeatedly ordering the same broad panel without a specific question.
Results should also be discussed before elective procedures or travel when a significant deficiency is suspected. Confirmed antibody or complement disorders can change vaccine planning, antibiotic precautions, access to emergency treatment, and the need to carry medical documentation. Those decisions require a defined diagnosis; an isolated borderline value is not enough.
References
- Diagnostic tests for primary immunodeficiency disorders: Classic and genetic testing 2024 (Review)
- Immunodeficiency: Complement disorders 2024 (Review)
- Primary Immunodeficiency Diseases – Immunoglobulin Disorders 2026 (Official Guidance)
- Complement Testing – Complement Deficiency and Anticomplement Therapeutic Response Monitoring 2025 (Official Guidance)
- Complement Blood Test 2024 (Official Patient Guidance)
- Common Variable Immunodeficiency 2025 (Review)
Disclaimer
Complement and immunoglobulin results require interpretation using age-adjusted ranges, symptoms, medication and infusion history, organ function, and specimen quality. This article is educational and cannot diagnose immune deficiency, autoimmune activity, infection, or a plasma-cell disorder. Seek urgent care for symptoms of meningitis, sepsis, severe pneumonia, or breathing difficulty.
